Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply

Benefits of Influenza Vaccination for Low-, Intermediate-, and High-Risk Senior Citizens

Kristin L. Nichol, J. Wuorenma, T. von Sternberg · Archives of Internal Medicine · 1998 · 488 citations

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza

Karl G. Nicholson, Anthony Colegate, Audino Podda et al. · The Lancet · 2001 · 442 citations

Vaccination, Vaccine Safety, Cross-protection +10

Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial

Th.M.E. Govaert, M Sprenger, Geert‐Jan Dinant et al. · Vaccine · 1994 · 132 citations

Vaccinology, Vaccination, Cross-protection +9

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

Norbert Hehme, H. Engelmann, W. K x FC nzel et al. · Medical Microbiology and Immunology · 2002 · 113 citations

Vaccination, Vaccine Safety, Vaccine Development +9

Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

Karl G. Nicholson, D. A. J. Tyrrell, Phillippa Harrison et al. · Journal of Biological Standardization · 1979 · 111 citations

Vaccination, Vaccine Development, Immunology +8